n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Experimental Neoplasms in 9 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was designed to determine if the addition of NS-398 to NPe6-induced PDT in single or fractionated dosing would result in greater tumor kill." | 1.33 | Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398. ( Fromm, D; Harvey, EH; Kessel, D; Webber, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qian, X | 1 |
| Zhang, J | 1 |
| Liu, J | 1 |
| Banu, NA | 1 |
| Daly, RS | 1 |
| Buda, A | 1 |
| Moorghen, M | 1 |
| Baker, J | 1 |
| Pignatelli, M | 1 |
| Duff, M | 1 |
| Stapleton, PP | 1 |
| Mestre, JR | 1 |
| Maddali, S | 1 |
| Smyth, GP | 1 |
| Yan, Z | 1 |
| Freeman, TA | 1 |
| Daly, JM | 1 |
| Benitah, SA | 1 |
| Valerón, PF | 1 |
| Lacal, JC | 1 |
| Harvey, EH | 1 |
| Webber, J | 1 |
| Kessel, D | 1 |
| Fromm, D | 1 |
| Smakman, N | 1 |
| Schaap, N | 1 |
| Snijckers, CM | 1 |
| Borel Rinkes, IH | 1 |
| Kranenburg, O | 1 |
| Crokart, N | 1 |
| Radermacher, K | 1 |
| Jordan, BF | 1 |
| Baudelet, C | 1 |
| Cron, GO | 1 |
| Grégoire, V | 1 |
| Beghein, N | 1 |
| Bouzin, C | 1 |
| Feron, O | 1 |
| Gallez, B | 1 |
| Sawaoka, H | 1 |
| Tsuji, S | 1 |
| Tsujii, M | 1 |
| Gunawan, ES | 1 |
| Sasaki, Y | 1 |
| Kawano, S | 1 |
| Hori, M | 1 |
| Pyo, H | 1 |
| Choy, H | 1 |
| Amorino, GP | 1 |
| Kim, JS | 1 |
| Cao, Q | 1 |
| Hercules, SK | 1 |
| DuBois, RN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
9 other studies available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Experimental Neoplasms
| Article | Year |
|---|---|
Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Infections; Cell Line; Chemokine CCL5; C | 2011 |
Reduced tumour progression and angiogenesis in 1,2-dimethylhydrazine mice treated with NS-398 is associated with down-regulation of cyclooxygenase-2 and decreased beta-catenin nuclear localisation.
Topics: 1,2-Dimethylhydrazine; Adenoma; Animals; Apoptosis; beta Catenin; Bromodeoxyuridine; Carcinogens; Ce | 2011 |
Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma.
Topics: Animals; Antineoplastic Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibi | 2003 |
ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; cdc42 GTP-Binding Protein; Cells, Cultured; Cycloo | 2003 |
Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398.
Topics: Animals; Colonic Neoplasms; Cyclooxygenase Inhibitors; Drug Administration Schedule; Drug Synergism; | 2005 |
NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation.
Topics: Animals; Carcinoma, Transitional Cell; Cell Division; Cyclooxygenase Inhibitors; Humans; Male; Mice; | 2005 |
Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Liver Neoplasms, Experi | 2005 |
Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Topics: Animals; Apoptosis; Cell Division; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 1999 |
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; Combined Modality Therapy; Cyclooxygenase 2; Cyc | 2001 |